Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce the appointment of Stephen Stamp as a Director of the Company and as Chief Financial Officer with immediate effect.
Stephen Stamp is an experienced public company CFO and has held senior positions in a number of significant healthcare companies including as Group Finance Director of Shire plc, when the company was listed on the London Stock Exchange and NASDAQ, Chief Operating Officer of Xanodyne Pharmaceuticals Inc and most recently with AIM quoted Ergomed plc, where he served initially as CFO before becoming CEO. Mr Stamp qualified as a Chartered Accountant at KPMG and is a member of the Institute of Chartered Accountants.
Mr Stamp is taking over from Nick Robbins-Cherry, who has resigned as a Director of the Company with immediate effect to pursue other career opportunities. Mr Robbins-Cherry will remain employed by the Company until the end of October 2019 to facilitate an orderly handover to Mr Stamp.
Rolf Stahel, Midatech's Chairman commented: "The Directors are delighted to welcome Stephen Stamp to the Board of Midatech as CFO. He brings a wealth of relevant financial, commercial and industry experience gained in a wide range of senior roles at major healthcare companies, in the UK and internationally, which will enable him to make a significant contribution to Midatech's future success. This is an exciting time for the Company and having someone of Stephen's financial pedigree joining will be a real asset. I would also like to thank Nick Robbins-Cherry for his significant contribution and commitment to the Company over the past five years since our IPO and I wish him all the success in his next career move."
Craig Cook, Chief Executive of Midatech, commented: "I am excited that Stephen has agreed to join Midatech as CFO. He is a high calibre finance professional whose career to date makes him very well suited to support the execution of our strategy at this important and exciting time for the Company. Stephen's exceptional track record of both operational and financial leadership within the healthcare sector will deliver real benefit to Midatech. I very much look forward to working closely with him to drive forward the development of our business as we focus on getting our clinical research assets through clinical development, approval, and onto successful commercialisation. Whist I am sorry that Nick is leaving, I wish him well for the future and at the same time Stephen's appointment represents a very positive development for Midatech."
Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies
The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Mr Stephen Anthony Stamp, aged 57.
Current Directorships and Partnerships
Previous Directorships and Partnerships (past 5 years)
Berkeley Advisers Limited
Storm Pharmaceuticals Inc
Ergomed Clinical Research FZ-LLC
Ergomed Center for Data Management and Statistics GmbH
Pharminvent regulatory s.r.o.
Ergomed Virtuoso sarl
Sound Opinion Limited
Harefield Pharmacovigilance Limited
Ergomed Clinical Research Limited
PSR Group BV
Ergomed Clinical Research Inc
Ergomed Clinical Research Co Ltd
As of the date of this announcement, Stephen Stamp holds no ordinary shares in the capital of the Company. It is intended that in due course, Mr Stamp will be granted options over 1,000,000 shares in the Company, subject to certain performance criteria.
Save as disclosed above there are no additional disclosures to be made in accordance with Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.